Clinical Trial Update: A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating rhuMab 2C4 with gemcitabine in ovarian, primary peritoneal, and fallopian tube cancers has completed enrollment, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• rhuMAb 2C4

Snippet

Sponsor: Genentech, Inc. | Conditions: Ovarian Cancer, Peritoneal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-06-10